Innovations and Challenges in Renal Cancer
Second Cambridge Conference
April 2006
Innovations and Challenges in Melanoma: Summary Statement from the Second Cambridge Conference
MB Atkins, MS Ernstoff, RA Figlin, KT Flaherty, DJ George, WG Kaelin, Jr, ED Kwon, TA Libermann, WM Linehan, DF McDermott, AC Ochoa, AJ Pantuck, BI Rini, MA Rosen, JA Sosman, VP Sukhatme, JW Vieweg, CG Wood, L King
Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics
WM Linehan, PA Pinto, R Srinivasan, M Merino, P Choyke, L Choyke, J Coleman, J Toro, G Glenn, C Vocke, B Zbar, LS Schmidt, D Bottaro, and L Neckers
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
W G Kaelin, Jr,
Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead
J Jones, and TA Libermann
Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?
A J Pantuck, AS Belldegrun, and RA Figlin
Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome
CG Wood
Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials
JS Lam, AJ Pantuck, AS Belldegrun, and RA Figlin
Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy
RH Thompson, H Dong and ED Kwon
Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma
DF McDermott
Arginase, Prostaglandins, and Myeloid Suppressor Cells in Renal Cell Carcinoma
AC Ochoa, A Zea, C Hernandez, and PC Rodriguez
Reversal of Tumor-Mediated Immunosuppression
J Vieweg, Z Su, P Dahm, and S Kusmartsev
Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang
MS Ernstoff, TS Crocenzi, JD Seigne, NA Crosby, BF Cole, JL Fisher, JC Uhlenhake, D Mellinger, C Foster, CJ Farnham, K Mackay, ZM Szczepiorkowski, SM Webber, AR Schned, RD Harris, RJ Noelle, RJ Barth, Jr, JA Heaney
Biologic Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma
BI Rini and WK Rathmell
Sorafenib in Renal Cell Carcinoma
KT Flaherty
Phase 2 Studies of Sunitinib and AG013736 in Patients With Cytokine-refractory Renal Cell Carcinoma
DJ George
The Role of mTOR Inhibitors in the Treatment of Advanced Renal Cancer
D Cho, S Signoretti, M Regan, JW Mier, MB Atkins
Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer
JA Sosman, I Puzanov, and MB Atkins
Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma
MA Rosen and MD Schnall
Controversies in Angiogenic Monitoring
RS Bhatt, P Seth, and VP Sukhatme
